More equitable testing for prostate cancer risk is on the horizon, as researchers report findings from the largest and most genetically diverse study of prostate cancer genes ever conducted.

Combining five existing drugs can keep a highly aggressive type of bone marrow cancer at bay for longer, an innovative trial has shown.

A major new study in the journal Nature reveals a ‘traffic light’ mechanism controlling genetic activity within cells – a system which could potentially be targeted by cancer drugs already in development.